extract: 2025-05-01-nejm-semaglutide-mash-phase3-liver

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -23,6 +23,12 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15*
+
+The multi-organ protection thesis strengthens: MASH resolution at 62.9% adds hepatic protection to existing cardiovascular and renal benefits. MASH is projected to become the leading cause of liver transplantation, so preventing progression could generate substantial late-stage cost savings. However, the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given clinical magnitude, likely because MASH progression to transplant takes decades, falling outside typical budget windows.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (extend)
+*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15*
+
+NEJM Phase 3 trial adds liver protection as a third major organ system: semaglutide achieves 62.9% MASH resolution vs 34.3% placebo, with some benefits independent of weight loss. Meta-analysis shows GLP-1 RAs reduce major CV events, portal hypertension, and all-cause mortality in MASH patients, creating a cardiovascular-renal-hepatic protection triad.
+
 ---
 
 Relevant Notes:

inbox/archive/.extraction-debug/2025-05-01-nejm-semaglutide-mash-phase3-liver.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md

@@ -7,9 +7,13 @@ date: 2025-05-01
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, semaglutide, MASH, NASH, liver-disease, organ-protection]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,10 @@ Phase 3 trial of semaglutide 2.4mg in patients with MASH and moderate or advance
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Third organ-protection pathway (after CV and kidney) strengthens the case that GLP-1s should be evaluated as multi-organ protective agents, not just weight loss drugs
 EXTRACTION HINT: The multi-organ protection thesis may justify reframing the existing GLP-1 claim from a weight-loss-economics frame to a metabolic-disease-prevention frame
+
+
+## Key Facts
+- Semaglutide 2.4mg achieved 62.9% resolution of steatohepatitis without worsening fibrosis vs 34.3% placebo in Phase 3 trial
+- Resmetirom (Rezdiffra) was approved for MASH in March 2024 as dedicated MASH therapy
+- MASH is projected to become the leading cause of liver transplantation
+- Value in Health Medicare study estimated only $28M in MASH savings from GLP-1s